Human IL-8 ELISA Set

Instructions for use

Catalogue numbers:	1x96 tests:	EA101292
	5x96 tests:	EA101293
	10x96 tests:	EA101294
	15x96 tests:	EA101295
	20x96 tests:	EA101296

For research use only

Fast Track Your Research……

Table of Contents

1. Intended use 2
2. Introduction 2
2.1. Summary 2
2.2. Basic principle of a typical ELISA method 2
3. Reagents provided and reconstitution 3
4. Materials required but not provided 3
5. Storage Instructions 3
6. Specimen collection, processing & storage 4
7. Safety & precautions for use 5
8. Plate Preparation 6
8.1. Capture Antibody 6
8.2. Preparation method 6
9. Assay Preparation 7
9.1. Assay Design 7
9.2. Preparation of Standard 7
9.3. Preparation of Biotinylated anti-IL-8Detection Antibody 8
9.4. Preparation of Streptavidin-HRP 8
10. Method 9
11. Data Analysis 10
12. Assay limitations 10
13. Performance Characteristics 11
13.1. Sensitivity 11
13.2. Specificity 11
14. Bibliography 11
15. References 11

Human IL-8 ELISA Set

1. Intended use

The OriGene IL-8 ELISA Set is intended for use in a 'do it yourself' solid phase sandwich ELISA for the *in-vitro* qualitative and quantitative determination of IL-8in supernatants, buffered solutions, serum, plasma samples and other body fluids. This assay will recognise both natural and recombinant human IL-8.

This kit has been configured for research use only.

2. Introduction

2.1. Summary

Interleukin 8 (IL-8) or CXCL8, Monocyte-Derived Neutrophil Chemotactic Factor (MDNCF), Neutrophil Activating Factor (NAF) and NAD-P1 is a chemokine secreted by monocytes, macrophages and endothelial cells. IL-8 chemoattracts and activates neutrophils.(1, 2, 3)

The predominant form of IL-8 is a 8.4kDa protein containing 72 amino acid residues, which includes five additional N-Terminal amino-acids. IL-8 contains the four conserved cysteine residues present in CXC chemokines and also contains the "ELR" motif common to CXC chemokines that binds to CXCR1 and CXCR2.(3.4)

Data indicate that IL-8 may participate in the pathogenesis of rheumatoid arthritis (5) via the induction of neutrophil-mediated cartilage damage (6), and psoriasis(7).A causative involvement of IL-8 is found within a broad range of clinico-pathological conditions : adult respiratory distress syndrome, asthma, bacterial infections, bladder cancer, graft rejection and influenza infection, due to the now known biological properties of IL-8.This cytokine especially in combinations with other neutrophil activating agents, may prove helpful in the treatment of patients suffering from granulocytopenia, severe infections against which antibiotics are not effective, and immunodeficiency caused by HIV (8)

2.2. Basic principle of a typical ELISA method

A capture Antibody highly specific for IL-8 is coated to the wells a microtitre strip plate. Binding of IL-8 samples and known standards to the capture antibodies and subsequent binding of the biotinylated anti-IL-8 secondary antibody to the analyte is completed during the same incubation period. Any excess unbound analyte and secondary antibody is removed. The HRP conjugate solution is then added to every well including the zero wells, following incubation excess conjugate is removed by careful washing. A chromogen substrate is added to the wells resulting in the progressive development of a blue coloured complex with the conjugate. The colour development is then stopped by the addition of acid turning the resultant final product yellow. The intensity of the produced coloured complex is directly proportional to the concentration of IL-8 present in the samples and standards. The absorbance of the colour complex is then measured and the generated OD values for each standard are plotted against expected concentration forming a standard curve. This standard curve can then be used to accurately determine the concentration of IL-8 in any sample tested.

3. Reagents provided and reconstitution

(Details below shown for the 5x96 Set)

Reagents (Store@2-8^{o}C)	**Quantity 5x96 well kit** Cat no. EA101293	**Reconstitution**
IL-8Standard: 2000pg/ml	5 vials	Reconstitute as directed on the vial (see Assay preparation, section9)
Capture Antibody	1 vial (0.3ml)	Sterile, dilute prior to use (see Plate preparation, section8)
Biotinylated anti-IL-8 Detection Antibody	1 vial	Reconstitute with 0.55ml of reconstitution buffer prior to use (see Assay preparation, section9)
Streptavidin-HRP	1 vial (25µl)	Dilute prior to use (see Assay preparation, section9)
TMB Substrate	2 vials (25ml)	Ready to use

4. Materials required but not provided

- 96 well Microtitre plates (e.g. Nunc Maxisorp Cat # 468667)
- Reconstitution Buffer (1xPBS, 0.09% Azide)
- Coating Buffer (1xPBS, pH 7.2-7.4)
- Wash Buffer (1xPBS, 0.05% Tween20)
- Blocking Buffer (1xPBS, 5% BSA)
- Standard and Secondary Antibody Dilution Buffer (1xPBS, 1% BSA)
- HRP Diluent Buffer (1xPBS, 1% BSA, 0.1% Tween20)
- Stop Reagent (1M Sulfuric Acid)
- Microtitre plate reader with appropriate filters (450nm required with optional 620nm reference filter)
- Microplate washer or wash bottle
- 10, 50, 100, 200 and1,000µl adjustable single channel micropipettes with disposable tips
- 50-300µl multi-channel micropipette with disposable tips
- Multichannel micropipette reagent reservoirs
- Distilled water
- Vortex mixer
- Miscellaneous laboratory plastic and/or glass, if possible sterile

5. Storage Instructions

Store kit reagents between 2and 8°C. Immediately after use remaining reagents should be returned to cold storage (2-8°C). Expiry of the reagents is stated on box front labels. The expiry of the components can only be guaranteed if the components are stored properly, and if, incase of repeated use of one component, the reagent is not contaminated by the first handling.

Reconstitution Buffer: Once prepared store at 2-8°Cfor up to one week
Coating Buffer: Once prepared store at 2-8°C for up to one week
Wash Buffer: Once prepared use immediately
Blocking Buffer: Once prepared store at 2-8°C for up to one week
Standard and Secondary Antibody Dilution Buffer: Once prepared store at 2-8°C for up to one week
HRP Diluent Buffer: Once prepared store at 2-8°C for up to one week

Reconstituted Biotinylated anti IL-8 Detection Antibody: Once prepared store at 2-8°C for up to one year
Reconstituted IL-8 Standard: Discard after use

6. Specimen collection, processing & storage

Cell culture supernatants, human serum, plasma or other biological samples will be suitable for use in theassay. Remove serum from the clot or red cells, respectively, as soon as possible after clotting andseparation.

Cell culture supernatants: Remove particulates and aggregates by spinning at approximately 1000 x g for 10 min.

Serum: Use pyrogen/endotoxin freecollecting tubes. Serum should be removed rapidly and carefully from the red cells after clotting. Following clotting, centrifuge at approximately 1000 x g for 10 min and remove serum.

Plasma: EDTA, citrate and heparin plasma can be assayed. Spin samples at 1000 x g for 30 min to remove particulates. Harvest plasma.

Storage: If not analyzed shortly after collection, samples should be aliquoted (250-500µl) to avoid repeated freeze-thaw cycles and stored frozen at –70°C. Avoid multiple freeze-thaw cycles of frozen specimens.

Recommendation: Do not thaw by heating at 37°C or 56°C. Thaw at room temperature and make sure that sample is completely thawed and homogeneous before use.When possible avoid use of badly haemolysed or lipemic sera. If large amounts of particles are present these should be removed prior to use by centrifugation or filtration.

7. Safety & precautions for use

- Handling of reagents, serum or plasma specimens should be in accordance with local safety procedures , e.g.CDC/NIH Health manual : " Biosafety in Microbiological and Biomedical Laboratories" 1984
- Avoid any skin contact with H_2SO_4 and TMB. In case of contact, wash thoroughly with water
- Do not eat, drink, smoke or apply cosmetics where kit reagents are used
- Do not pipette by mouth
- When not in use, kit components should be stored refrigerated or frozen as indicated on vials or bottles labels
- All reagents should be warmed to room temperature before use. Lyophilized standards should be discarded after use
- Cover or cap all reagents when not in use
- Do not mix or interchange reagents between different lots
- Do not use reagents beyond the expiration date of the kit
- Use a clean disposable plastic pipette tip for each reagent, standard, or specimen addition in order to avoid cross contamination, for the dispensing of H_2SO_4 and substrate solution, avoid pipettes with metal parts
- Use a clean plastic container to prepare the washing solution
- Thoroughly mix the reagents and samples before use by agitation or swirling
- All residual washing liquid must be drained from the wells by efficient aspiration or by decantation followed by tapping the plate forcefully on absorbent paper. Never insert absorbent paper directly into the wells
- The TMB solution is light sensitive. Avoid prolonged exposure to light. Also, avoid contact of the TMB solution with metal to prevent colour development. Warning TMB is toxic avoid direct contact with hands. Dispose off properly
- If a dark blue colour develops within a few minutes after preparation, this indicates that the TMB solution has been contaminated and must be discarded. Read absorbance’s within 1 hour after completion of the assay
- When pipetting reagents, maintain a consistent order of addition from well-to-well. This will ensure equal incubation times for all wells
- Follow incubation times described in the assay procedure
- Dispense the TMB solution within 15 min of the washing of the microtitre plate

8. Plate Preparation

8.1. Capture Antibody

For one plate add 50µl of Capture Antibody into 10mL of Coating Buffer

8.2. Preparation method

1.	Addition	Add 100µl of diluted **Capture Antibody** to every well
2.	Incubation	Cover with a plastic plate cover and incubate at 4°C **overnight**
3.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.4 ml of **washing solution** into each well c) Aspirate the contents of each well d) Repeat step b and c
4.	Addition	Add 250µl of **Blocking Buffer** to every well
5.	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for **2 hour(s)**
6.	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.4 ml of **washing solution** into each well c) Aspirate the contents of each well d) Repeat step b and c another 2 times
For Immediate use of the plate(s) continue to section 9. If you wish to store the coated and blocked plates for future use bench dry each plate at room temperature (18 to 25°C) for 24 hours. Cover the plates and then store at 2-8°C in a sealed plastic bag with desiccant for up to 12months.		

9. Assay Preparation

Bring all reagents to room temperature before use

9.1. Assay Design

Determine the number of microwell strips required to test the desired number of samples plus appropriate number of wells needed for running zeros and standards. Each sample, standard and zero should be tested **in duplicate**.

Example plate layout(example shown for a 6 point standard curve)

	Standards		Sample Wells									
	1	2	3	4	5	6	7	8	9	10	11	12
A	2000	2000										
B	1000	1000										
C	500	500										
D	250	250										
E	125	125										
F	62.5	62.5										
G	zero	zero										
H												

All remaining empty wells can be used to test samples in duplicate

9.2. Preparation of Standard

Standard vials must be reconstituted with the volume of standard dilution buffer shown on the vial immediately prior to use. This reconstitution gives a stock solution of 2000pg/ml of IL-8. **Mix the reconstituted standard gently by inversion only**. Serial dilutions of the standard are made directly in the assay plate to provide the concentration range from 2000 to 62.5pg/ml. A fresh standard curve should be produced for each new assay.

- Immediately after reconstitution add 200µl of the reconstituted standard to wells A1 and A2, which provides the highest concentration standard at 2000pg/ml
- Add 100µl of appropriate standard diluent to the remaining standard wells B1 and B2 to F1 and F2
- Transfer 100µl from wells A1 and A2 to B1 and B2. Mix the well contents by repeated aspirations and ejections taking care not to scratch the inner surface of the wells
- Continue this 1:1 dilution using 100µl from wells B1 and B2 through to wells F1 and F2 providing a serial diluted standard curve ranging from 2000pg/ml to 62.5pg/ml
- Discard 100µl from the final wells of the standard curve (F1 and F2)

Alternatively these dilutions can be performed in separate clean tubes and immediatelytransferred directly into the relevant wells.

9.3. Preparation of Biotinylated anti-IL-8 Detection Antibody

It is recommended this reagent is prepared **immediately before use**. Dilute the reconstituted biotinylated anti-IL-8 with the biotinylated antibody diluent in an appropriate clean glass vial.

For one plate add 100µl of the reconstituted Detection Antibody into 5mL of Biotinylated Antibody dilution buffer.

Please note for 1 x 96 tests, Biotinylated Detection Antibody is provided in liquid form.

9.4. Preparation of Streptavidin-HRP

It is recommended to centrifuge vial for a few seconds in a microcentrifuge to collect all the volume at the bottom.

Dilute 5µl of Streptavidin-HRP into 0.5ml of HRP diluent buffer**immediately before use.**
Take 150µl of the diluted HRP solution into 10mL of HRP diluent buffer.

Do-not keep these solutions for future experiments.
.

10. Method

We strongly recommend that every vial is mixed thoroughly without foaming prior to use except the standard vialwhich must be mixed gently by inversion only.

Note: Final preparation of Biotinylated anti-IL-8 (section 9.3) and Streptavidin-HRP (section 9.4) should occur immediately before use.

Assay Step		Details
1	Preparation	**Prepare Standard curve** as shown in Section 9.2
2	Addition	Add 100µl of each **standard, sample, zero** (Standard Dilution Buffer) to appropriate wells in duplicate
3	Addition	Add 50µl of diluted **Detection Antibody** into all wells
4	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for **1 hour**
5	Wash	Remove the cover and wash the plate as follows: a) Aspirate the liquid from each well b) Dispense 0.4 ml of **washing solution** into each well c) Aspirate the contents of each well d) Repeat step b and c
6	Addition	Add 100µl of **Streptavidin-HRP** solution into all wells
7	Incubation	Cover with a plastic plate cover and incubate at room temperature (18 to 25°C) for **30 mins**
8	Wash	Repeat wash step 5.
9	Addition	Add 100µl of ready-to-use **TMB Substrate Solution** into all wells
10	Incubation	Incubate in the dark for **5-15 minutes*** at room temperature. Avoid direct exposure to light by wrapping the plate in aluminium foil.
11	Addition	Add 100µl of **H_2SO_4:Stop Reagent** into all wells
Read the absorbance value of each well (immediately after step 11.) on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm as the reference wave length (610 nm to 650 nm is acceptable).		

***Incubation time of the substrate solution is usually determined by the ELISA reader performance. Many ELISA readers only record absorbance up to 2.0 O.D. Therefore the colour development within individual microwells must be observed by the analyst, and the substrate reaction stopped before positive wells are no longer within recordable range*

11. Data Analysis

Calculate the average absorbance values for each set of duplicate standards and samples**.**Ideally duplicates should be within 20% of the mean.

Generate a linear standard curve by plotting the average absorbance of each standard on the vertical axis versus the corresponding IL-8standard concentration on the horizontal axis.

The amount of IL-8in each sample is determined by extrapolating OD values against IL-8standard concentrations using the standard curve**.**

12. Assay limitations

Do not extrapolate the standard curve beyond the maximum standard curve point. The dose-response is non-linear in this region and good accuracy is difficult to obtain. Concentrated samples above the maximum standard concentration must be diluted with Standard diluent or with your own sample buffer to produce an OD value within the range of the standard curve. Following analysis of such samples always multiply results by the appropriate dilution factor to produce actual final concentration.

The influence of various drugs on end results has not been investigated. Bacterial or fungal contamination and laboratory cross-contamination may also cause irregular results.

Improper or insufficient washing at any stage of the procedure will result in either false positive or false negative results. Completely empty wells before dispensing fresh Washing Buffer, fill with Washing Buffer as indicated for each wash cycle and do not allow wells to sit uncovered or dry for extended periods.

Disposable pipette tips, flasks or glassware are preferred, reusable glassware must be washed and thoroughly rinsed of all detergents before use.

As with most biological assays conditions may vary from assay to assay therefore**afresh standard curve must be prepared and run for every assay.**

13. Performance Characteristics

13.1. Sensitivity

The sensitivity, minimum detectable dose of this IL-8antibody pair was determined using theOriGeneIL-8ELISA kit (which contains the same antibodies) and was found to be **<29pg/ml**. This was determined by adding 3 standard deviations to the mean OD obtained when the zero standard was assayed 30 times.

13.2. Specificity

The assay recognizes natural human IL-8. To define specificity of this IL-8 antibody pair, several proteins were tested for cross reactivity using theOriGeneIL-8 pre-coated ELISA kit (which contains the same antibodies).There was no cross reactivity observed for any protein tested (IL-1α, IL-1β, IL-10 IL-12, IFNγ, IL-2, IL-6, TNFα, IL-4 and IL-13).

14. Bibliography

Wolff b, Burns AR, Middleton J, Rot A. J. Exp. Med. 1998 Nov 2;188(9):1757-62
Utgaard JO, Jahnsen FL, Bakka A, Brandtzaeg P, Haraldsen G. J. Exp. Med.1998 Nov 2;188(9):1751-6
Baggiolini M, Clark-Lewis I (1992). FEBS Lett. 307 (1):97-101
Matsushima, K. et al (1988) J. Exp. Med. 167, 1883-1893.
Peichl P., M. Ceska, H.Broell, F. Effenberger, and I. J. D. Lindley. (1992) Annals of the Rheumatic Diseases 51, 19-22.
Elford, P. R. , and P. H. Cooper . (1991) Arthritis and Rheumatism 34, 325-332
Gearing, A. J. H. , N. J. Fincham, C. R. Bird, M. Wadhwa, A. Meager, J. E. Cartwright, and R. D. R. Camp. (1990) Cytokine 2, 68-75
Matsushima, K. and J.J. Oppenheim. (1989). Cytokine 1, 2-13.

15. References

Bjorkholm B. M. et al., J. Biol. Chem., 2002; 277(37): 34191 -34197
Kaci, G. et al., Appl. Envir. Microbiol.,2011; 77 (13): 4681-4684
Nilsson C. et al., Infect. Immun., 2003; 71(11): 6573 – 6581
Peric, M.et al., J. Immunol., 2008;181(12): 8504-8512.
Preising, J. et al.,Appl. Envir. Microbiol., 2010;76(9): 3048-3051

TECHNICAL CONSULTATION

OriGene Technologies, Inc.
9620 Medical Center Dr., Suite 200
Rockville, MD 20850

Phone: 1.888.267.4436
Fax: 301-340-9254
Email: techsupport@origene.com
Web: www.origene.com

For Research Use Only
Not for use in diagnostic procedures